Astrazeneca Pharma India Ltd vs Cipla Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 15, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8387 as of 15 May 12:42 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Cipla Ltd changed from 27.3 on March 2021 to 22.1 on March 2025 . This represents a CAGR of -4.14% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Cipla Ltd changed from ₹ 65746 crore on March 2021 to ₹ 116434 crore on March 2025 . This represents a CAGR of 12.11% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Cipla Ltd for the Mar '26 is ₹ 6689 crore as compare to the Dec '25 revenue of ₹ 7280 crore. This represent the decline of -8.12% The ebitda of Astrazeneca Pharma India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Cipla Ltd for the Mar '26 is ₹ 1103 crore as compare to the Dec '25 ebitda of ₹ 1185 crore. This represent the decline of -6.95% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Cipla Ltd changed from ₹ 1176 crore to ₹ 550.11 crore over 8 quarters. This represents a CAGR of -31.61% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Cipla Ltd changed from 16.34 % on March 2021 to 25.05 % on March 2025 . This represents a CAGR of 8.92% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Cipla Ltd

Cipla Limited is one of the leading pharmaceutical companies in India.
The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Cipla Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Cipla Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,875 Cr while Market cap of Cipla Ltd is 116,211 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Cipla Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Cipla Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Cipla Ltd?

As of May 15, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8350.1. On the other hand, Cipla Ltd stock price is INR ₹1438.65.

How do dividend payouts of Astrazeneca Pharma India Ltd and Cipla Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Cipla Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.